CoChat

Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management

Open access

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index; 60 of the 159 sources its claims cite were checked for support.

Abstract

Benzodiazepine (BZD) receptor agonists, commonly known as Z-drugs, are non-BZD hypnotics primarily prescribed for the treatment of insomnia. Their use is recommended for no longer than four weeks to minimize the risk of adverse effects, including dependence and withdrawal. However, these guidelines are frequently disregarded, and the abuse of and dependence on Z-drugs has emerged as a growing public health concern in Brazil. The present article reviews the current evidence on Z-drug use disorder-including dependence and withdrawal-and proposes clinical guidelines for the management of discontinuation. The recommendations were developed based on a systematic review of the literature and refined using the Delphi methodology. The consensus was developed by a multidisciplinary task force, with coordination and voting led by a steering committee. An advisory committee, consisting of neurologists from the Brazilian Academy of Neurology (Academia Brasileira de Neurologia, ABN, in Portuguese) and psychiatrists specializing in substance-use disorders, contributed to the selection and organization of the scientific literature and took part in the voting process. Key recommendations were established: 1) prior to discontinuation, a comprehensive assessment of mental status, psychiatric and sleep comorbidities, and the degree of pharmacological dependence is essential; 2) gradual tapering is advised; 3) non-pharmacological interventions, such as cognitive behavioral therapy for insomnia, are recommended, and acceptance and commitment therapy, which is optional, may be incorporated; 4) for zolpidem withdrawal, adjunctive pharmacotherapy, which is optional, may include trazodone, other antidepressants, quetiapine or other antipsychotics, alpha-2-delta (α2δ) ligands, or alternative hypnotics (such as ramelteon, zopiclone, and eszopiclone); 5) for Z-drug discontinuation, intermediate- or long-acting BZDs are recommended; and 6) short- or ultra-short-acting BZDs and immediate-release melatonin are not recommended. © 2025 Associacao Arquivos de Neuro-Psiquiatria. All rights reserved.

Overview

CoChat Summary

## TL;DR

This Brazilian Academy of Neurology guideline reviews evidence on Z-drug dependence and withdrawal and proposes Delphi-based recommendations for deprescribing. It concludes that assessment of comorbidities and dependence severity is essential, gradual tapering is advised, CBT-I is recommended, and adjunctive pharmacotherapy is only optional in selected cases.

## Key findings

  • The guideline developed 29 PICO research questions: 18 on deprescribing, 4 on abstinence, and 7 on dependence/abuse.
  • The deprescribing review included 13 articles; only 6 were randomized controlled trials (RCTs). The abstinence review included 38 articles, 30 of which were case reports. The dependence review included 24 articles.
  • The highest level of evidence was level 2 for PICO 1.1 (effect of CBT-I on weaning from Z-drugs for insomnia); all other questions were rated levels 3 to 5.
  • In a systematic review of Z-drug withdrawal cases, the authors identified 43 reports published between 1990 and 2025; 93.0% involved zolpidem, 7.0% zopiclone, and none involved zaleplon or eszopiclone. Among seizure cases, 24 epileptic seizures were described, with a median maximum dose of 250 mg and a median abstinence period of 30 hours before seizure onset.

## Methods

  • Design: Clinical guideline/consensus statement developed from systematic reviews and refined using the Delphi method, with evidence graded using the Oxford Centre for Evidence-Based Medicine (OCEBM) levels.
  • Data/sample: The task force created 29 PICO questions and reviewed articles for deprescribing, abstinence, and dependence/abuse; the final evidence base included 13 deprescribing articles, 38 abstinence articles, and 24 dependence articles.
  • Main analysis: Articles were individually assigned evidence levels, then recommendations were voted on in up to three Delphi rounds with a 66% consensus threshold; a steering committee and advisory committee reviewed all items and could modify consensus status.

## Limitations

  • The paper explicitly states that meta-analyses could not be performed because of the limited number of studies and high methodological heterogeneity.
  • It also states that the evidence base is generally low quality and that many recommendations rely on expert opinion because of the scarcity of high-level studies.
  • The paper notes that many experts had limited or no experience with medications not available in Brazil (such as DORAs and extended-release melatonin), which may have influenced recommendations; it also says not all psychotherapeutic approaches were evaluated and that the absence of psychologists with expertise in those modalities may have limited the non-pharmacological recommendations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1055/s-0045-1812323

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Notes: * Z-drug abuse includes any deviation from prescribed use (such as exceeding dosage, frequency, or duration) or using the drug without a prescription, often involving risky combinations with alcohol or other substances. ‡ The criteria to consider hospital-based tapering should include the presence of any of the following: 1) History of alcohol or other substance use disorders; 2) previous episodes of drug withdrawal-related seizures; 3) presence of severe medical and/or psychiatric comorbidities; 4) use of high doses of Z-drugs; and/or 5) concurrent use of psychostimulants or opioids. Flowchart for Z-drug deprescription.
Figure 1 Notes: * Z-drug abuse includes any deviation from prescribed use (such as exceeding dosage, frequency, or duration) or using the drug without a prescription, often involving risky combinations with alcohol or other substances. ‡ The criteria to consider hospital-based tapering should include the presence of any of the following: 1) History of alcohol or other substance use disorders; 2) previous episodes of drug withdrawal-related seizures; 3) presence of severe medical and/or psychiatric comorbidities; 4) use of high doses of Z-drugs; and/or 5) concurrent use of psychostimulants or opioids. Flowchart for Z-drug deprescription.CC BY · PubMed Central

Verification

Claims the paper makes

44 Valid · 6 Not valid · 54 Not checked · 57 Own results and interpretations

85 more claims · 21 with their cited sources checked

Create a free account to see all 161 claims and to verify the 17 references still open.

See all claims — free account
  • It may state two separate claims as one. 49
  • Probably not a substantial claim. 26

Create a free account to see these claims.

Citations

Cites

Show all 91 references

Research works printed but not linked: 7

  1. Agência Nacional de Vigilância Sanitária (Anvisa), 2024, Medicamento zolpidem terá alteração no tipo de receita para prescrição e venda
  2. W C Becker, 2025, Prescription drug misuse: Epidemiology, prevention, identification, and management
  3. 2023, FDA requiring lower recommended dose for certain sleep drugs containing zolpidem
  4. American Academy of Sleep Medicine, 2023, International Classification of Sleep Disorders – Third Edition, Text Revision (ICSD-3-TR)
  5. National Institute for Health and Care Excellence (NICE), 2022, Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults
  6. K Pottie, 2018, Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline, Can Fam Physician, 64, 339
  7. Kayser Permanente National Mediation Committee. National Permanente Medical Groups, 2021, Clinician Practice Recommendations for Benzodiazepines & Non-Benzodiazepines Sedative-Hypnotics/Z-Drugs (For Adults ≥ 18 Years Old)

Cited by

See all 1

Metadata

Authors
Stelzer, F. G., Bacelar, A., Éckeli, A. L., Negrão, A. B., Almeida, C. M. O., Franco, C. M. R., Pires, G. N., Gitaí, L. L. G., Sobreira-Neto, M. A., Assis, M., Mei, P. A., Hasan, R., Martinez, S. C. G., Marchiori, T., Fidalgo, T. M., Siqueira, L. L. D., & Poyares, D.
Affiliations
  • Universidade de São Paulo (BR)
  • Fundação Planetário da Cidade do Rio de Janeiro (BR)
  • Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Neurociências e Ciências do Comportamento, Ribeirão Preto SP, Brazil.
  • Universidade do Estado do Amazonas (BR)
  • Universidade Federal de Pernambuco (BR)
  • Instituto do Sono (BR)
  • Centro Universitário Cesmac (BR)
  • Universidade Federal do Ceará (BR)
  • Hospital São Lucas, Curitiba PR, Brazil.
  • Universidade Federal de São Carlos (BR)
  • Hospital da Restauração (BR)
  • Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Neurologia, Campinas SP, Brazil.
Venue
Arquivos de Neuro-Psiquiatria
Published
2025-10
Volume
83
Issue
10
Pages
001-024
ISSN
  • 0004-282X (ISSN-L)
  • 1678-4227
OpenAlex
W4415892655
Cited by
1
References
90
Citations by year
2026: 1
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • Arquivos de Neuro-Psiquiatria (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
Z-drugs, benzodiazepine receptor agonists, hypnotic dependence, gradual tapering, cognitive behavioral therapy for insomnia, acceptance and commitment therapy, trazodone, gabapentinoids, melatonin, insomnia treatment, substance use disorders
MeSH terms
Benzodiazepines, Brazil, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Substance Withdrawal Syndrome, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management. https://app.cochat.ai/papers/10.1055/s-0045-1812323
The paper
Stelzer, F. G., Bacelar, A., Éckeli, A. L., Negrão, A. B., Almeida, C. M. O., Franco, C. M. R., Pires, G. N., Gitaí, L. L. G., Sobreira-Neto, M. A., Assis, M., Mei, P. A., Hasan, R., Martinez, S. C. G., Marchiori, T., Fidalgo, T. M., Siqueira, L. L. D., & Poyares, D. (2025). Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1055/s-0045-1812323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.